FXR activation treats PBC by depressing cholesterol 7α-hydroxylase/bile acid transporters, inducing the production of fibroblast growth factor-19 (FGF-19), a negative regulator of bile acid synthesis, and up-regulating organic solute transporters and the bile salt export pump. The gene discussed is FGF19; the disease is primary biliary cholangitis.